Clinical trial
Randomized, Double-blind, Active -Controlled Trial to Assess Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine, Including Revaccination, in Elderly Subjects
NCT01013675 is registered in ClinicalTrials.gov with Abbott Biologicals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Active -Controlled Trial to Assess Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine, Including Revaccination, in Elderly Subjects
- Lead sponsor
- Abbott Biologicals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- April 30, 2011
- Enrollment
- 622 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
influenza vaccines